FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging

Clin Imaging. 2017 Mar-Apr:42:126-132. doi: 10.1016/j.clinimag.2016.11.016. Epub 2016 Nov 29.

Abstract

Objective: To assess the feasibility of positron emission tomography/magnetic resonance imaging (PET/MR) with 18F-fluordeoxyglucose (FDG) for initial staging of sarcoma.

Materials and methods: Twenty-nine patients with sarcoma were included in this study. Weighted kappa (κ) was used to assess the agreement between PET/MR and conventional imaging (CT and MR). The accuracy of PET/MR and conventional imaging for distant metastases was compared using receiver operating characteristic (ROC) analysis.

Results: T and M stage were identical for PET/MR and conventional modalities in all patients (κ=1). N stage was identical for 28/29 patients (κ=0.65).

Conclusions: FDG PET/MR shows excellent agreement with the currently preferred imaging methods (CT and MR) in initial staging of sarcoma.

Keywords: PET/MR; Sarcoma; Staging.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Bone Neoplasms / diagnostic imaging*
  • Bone Neoplasms / pathology
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Multimodal Imaging / methods*
  • Neoplasm Staging
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals
  • Sarcoma / diagnostic imaging*
  • Sarcoma / pathology
  • Soft Tissue Neoplasms / diagnostic imaging*
  • Soft Tissue Neoplasms / pathology
  • Tomography, X-Ray Computed / methods
  • Young Adult

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18